Misplaced expanding beads may pose danger to children’s ears

By Andrew M. Seaman (Reuters Health) – Small beads that expand in water and are often marketed as toys have the potential to cause hearing loss if the products get lodged in children’s ears, according to a new report. “The general rule is for kids under six years of age, these are the things I would keep out of the home,” said Dr. Gary Smith, who is president of the Child Injury Prevention Alliance. Parents of older children using these types of super-absorbent polymer beads should keep track of the objects “so nothing bad happens,” said Smith, who was not among the authors of the new report.
Go to Source

Cephalon, U.S. states reach $125 million settlement over generic drugs

By Sarah N. Lynch WASHINGTON (Reuters) – Cephalon has reached a $125 million settlement with 48 states in connection with its alleged efforts to delay generic versions of its blockbuster sleep disorder drug Provigil from entering the market, New York Attorney General Eric Schneiderman said on Thursday. The settlement with Cephalon, now owned by Teva Pharmaceuticals, comes a little more than a year after the company struck a $1.2 billion parallel settlement with the Federal Trade Commission.
Go to Source

U.S. health researchers launch Zika vaccine clinical trial

Dr. Howard Zucker, the Commissioner of the New York State Department of Health unveiled a Zika Prevention Kit for pregnant women during the rollout of a Zika Information hotline and website, in New YorkBy Will Dunham WASHINGTON (Reuters) – U.S. government researchers said on Wednesday they have begun their first clinical trial of a Zika vaccine as concerns over the mosquito-borne virus mount following the first cases of local transmission in the continental United States. There is no approved vaccine or drug for Zika, a virus spreading rapidly in the Americas that can cause the birth defect microcephaly, marked by small head size that can lead to severe developmental problems in babies. The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health federal research agency, said its early-stage clinical trial will involve at least 80 healthy volunteers ages 18 to 35 at three study sites.

Go to Source

1 7 8 9 10